Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Marion van Mackelenbergh, Eva Ciruelos et al.|Nature Medicine|2024Cited by 8
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancerMarina Elena Cazzaniga, Maureen Trudeau, Daniele Generali et al.|JNCI Cancer Spectrum|2023Cited by 3